This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): alprostadil, Bondil
Description: MUSE is a formulation of alprostadil given as a urethral suppository. It was developed in order to make alprostadil locally available without an injection. Alprostadil is identical to naturally occuring prostaglandin E1 (PGE1). It works by causing relaxation of the trabecular smooth muscle and dilation of cavernousarteries, leading to expansion of lacunar spaces and entrapment of blood.
In November 2000, Vivus granted Paladin Labs the exclusive rights to distribute and market MUSE in Canada.
In April 2008, Vivus announced that it entered into a $30 million funding collaboration with Deerfield Management. Under the terms of the agreements, Deerfield will provide funds for the Phase III program for avanafil. The funding will be provided by Deerfield from two sources: $20 million under a Royalty and Funding Agreement in the first 18 months of the collaboration and $10 million from the sale of Vivus common stock.
In consideration for the funding, Deerfield will receive a royalty on product sales of MUSE and if approved, product sales of avanafil. VIVUS and Deerfield have also entered into an Option and Put Agreement that allows Vivus to purchase the royalty stream from Deerfield and allows Deerfield, under certain conditions, to require Vivus to purchase the royalty stream from Deerfield. Vivus, entirely at its discretion, can...See full deal structure in Biomedtracker
Pink Sheet Ares-Serono Group
Pink Sheet Serono Labs
Pink Sheet In Brief: Vivus' Muse
Additional information available to subscribers only: